NeoGenomics: Distribution Moat In Community Oncology [Seeking Alpha]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Seeking Alpha
NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration. NEO trades at a significant discount to sector peers on EV/Sales and P/S, offering a margin of safety if execution on MRD and margin expansion materializes. Tom Werner/DigitalVision via Getty Images NeoGenomics ( NEO ) is executing a pivot from being a commodity diagnostic service provider to being a comprehensive precision oncology platform. While the market has focused intensely on the first mover advantages offered by the MRD monitoring companies, I believe that the This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any su
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026Business Wire
- NeoGenomics (NASDAQ:NEO) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- NeoGenomics (NASDAQ:NEO) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.MarketBeat
- NeoGenomics sees Q4 revenue of about $190M [Seeking Alpha]Seeking Alpha
- NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 10/28/25 - Beat
NEO
Sec Filings
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- 1/15/26 - Form 4
- NEO's page on the SEC website